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OBJECTIVES We sought to assess the effects of low density lipoprotein (LDL)-apheresis (LDL-A) for
regression of coronary plaque in familial hypercholesterolemia (FH), we set up a one-year
follow-up multicenter trial using coronary angiography and intravascular ultrasound (IVUS).
BACKGROUND It is still unclear whether aggressive lipid-lowering therapy by LDL-A leads to the regression
of coronary plaque in patients with FH.
METHODS Eighteen patients with FH were assigned to one of two groups: medication  LDL-A
(LDL-A group, n  11) and medication only (medication group, n  7). Total cholesterol,
triglycerides, high density lipoprotein cholesterol and LDL cholesterol were measured in all
subjects at the outset of treatment (baseline) and every three months thereafter. Coronary
angiography and IVUS were performed at the outset and after the one-year follow-up period
to measure minimal lumen diameter (MLD) by coronary angiogram and plaque area (PA) by
IVUS.
RESULTS The LDL-A group showed 28.4% reduction in total cholesterol (from 275  27 mg/dl to
197  19 mg/dl) and 34.3% reduction in LDL cholesterol (from 213  25 mg/dl to 140 
27 mg/dl) after one-year follow-up, while the medication group showed no changes in
cholesterol levels. There were significant interactions between both treatments in total
cholesterol (p  0.0001), LDL cholesterol (p  0.0001), MLD (p  0.008) and PA (p 
0.017) using two-way repeated-measures analysis of variance by the SAS system (SAS
Institute Inc., Cary, North Carolina). Significant differences were seen in net change in MLD
(p  0.004) and PA (p  0.008) during the one-year follow-up period between both groups.
CONCLUSIONS These results suggest that aggressive lipid-lowering therapy using the combination of LDL-A
and lipid-lowering drugs may induce regression of coronary atherosclerotic plaque in FH
patients. (J Am Coll Cardiol 2002;40:220–7) © 2002 by the American College of
Cardiology Foundation
Recent large-scale clinical trials of lipid-lowering drugs have
demonstrated that intensive lowering of total cholesterol
orlow density lipoprotein (LDL) cholesterol may retard
progression of coronary atherosclerosis and lower the inci-
dence of cardiac events despite the relatively small changes
in the severity of lesions demonstrated in angiographic trials
(1–8). True regression of coronary lesions has not been-
proven using angiography; mainly slowing or stopping
progression of luminal narrowing, as measured by minimal
lumen diameter (MLD), has been reported. Percent stenosis
can be misleading as a narrowing of the reference segment
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more than the MLD could lead to an erroneous result of
“regression.”
Recent progress in intravascular ultrasound (IVUS) im-
aging has enabled quantitative diagnosis of coronary plaque
size, which cannot be made by coronary angiography. The
most pressing concern in the field is to determine how
lipid-lowering therapy contributes to regression and stabi-
lization of coronary plaques in the course of secondary
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prevention of cardiac events, and how it prevents the
occurrence of acute coronary syndrome. Although there are
many study reports evaluating the effects of lipid-lowering
therapy by angiography, studies using IVUS are limited. As
far as we are aware, no IVUS study has been performed to
evaluate whether aggressive cholesterol-lowering therapy by
low density lipoprotein-apheresis (LDL-A) reduces pro-
gression of coronary artery plaque in patients with familial
hypercholesterolemia (FH). For this reason, our study is
important because IVUS measurements did in fact show
regression of plaque.
The present report was designed as a prospective multi-
center study of drug refractory heterozygous FH patients
with coronary artery disease. The objective was to evaluate
the effects of aggressive lipid-lowering therapy, in this case
the combination of LDL-A and standard lipid-lowering
drugs, on regression of coronary plaques using computer-
assisted analysis of quantitative coronary angiogram (QCA)
and IVUS.
METHODS
Subjects. In this trial, 19 patients with heterozygous FH
(14 men, 5 women) were recruited from eight clinical
centers. Patients who met the following criteria were in-
cluded: 20 to 70 years old, LDL cholesterol measuring 130
to 230 mg/dl at least once in the six months before
registration and on a strict lipid-lowering diet and on
hepatic hydroxymethylglutaryl-coenzyme A (HMG-CoA)
reductase inhibitors administrated (pravastatin [20 mg/day]
or simvastatin [10 mg/day]), history of cardiac events—that
is, myocardial infarction (MI), angina pectoris, asymptom-
atic myocardial ischemia, coronary artery bypass graft sur-
gery (CABG) or percutaneous transluminal coronary angio-
plasty (PTCA), or with50% stenosis of coronary artery on
coronary angiogram. Patients were excluded if they were
pregnant or if they had suffered MI or unstable angina
pectoris within the previous three months; had undergone
PTCA or CABG within the previous six months; had
severe diabetes mellitus; had severe hypertension; had im-
paired hepatic or renal function; or had secondary hyper-
cholesterolemia.
Although all patients were recommended for the LDL-A
treatment because of their high LDL cholesterol levels and
history of coronary heart disease (CHD), patients who
refused LDL-A were included in the medication group.
Patients were allocated to either the LDL-A group, receiv-
ing biweekly LDL-A  HMG-CoA reductase inhibitor
(pravastatin [20 mg/day] or simvastatin [10 mg/day]) (n 
12), or the medication group, receiving HMG-CoA reduc-
tase inhibitor treatment alone (n  7). Combined use of
other lipid-lowering drugs (probucol, cholestyramine and
fibrate) was approved in addition to the HMG-CoA reduc-
tase inhibitor. Patients gave informed consent to participate
in this study, which was approved by each institutional’s
ethics committee.
Determination of blood parameters. In the medication
group, lipids (total cholesterol, triglycerides, high density
lipoprotein [HDL] cholesterol) were measured every three
months. In the LDL-A group, total cholesterol, triglyceride
and HDL cholesterol concentrations were measured before
and immediately after each LDL-A. The LDL cholesterol
concentration was calculated using the following formula:
LDL cholesterol]  [total cholesterol] 
[tHDL cholesterol]  [triglycerides] /5
Time-averaged concentrations (TAC) of total cholesterol
and LDL cholesterol in the LDL-A group had to be
calculated by applying a formula:
TAC  Cmin  0.73 [Cmax  Cmin])
where Cmin equals post-treatment level and Cmax equals
pretreatment level, as reported by Kroon et al. (9). For
triglycerides and HDL cholesterol, only pretreatment levels
were used in the analysis because triglyceride returned to
pretreatment levels within a few days after LDL-A, and
HDL cholesterol was not influenced.
LDL-A. The LDL-A was performed using an automated
system with two small-sized dextran sulfate cellulose col-
umns (Liposorber LA-15 columns installed in an MA-01
Unit, Kaneka Corporation, Osaka, Japan). In this system, a
polysulfone membrane separator separates the plasma, and
apolipoprotein B-containing lipoproteins are adsorbed in
one of two columns containing cellulose beads covalently
bound with dextran sulfate used in rotation in an extracor-
poreal circuit. The total amount of plasma treated by each
procedure was not 1.5 times the patient’s total plasma
volume (50 ml/kg body weight), and the treated plasma
volume was 3,000 to 4,000 ml for the purpose of reducing
total cholesterol levels to 100 mg/dl immediately after
LDL-A. The LDL-A treatment was repeated in the out-
patient clinic biweekly.
Abbreviations and Acronyms
ANOVA  analysis of variance
CABG  coronary artery bypass graft surgery
CAD  coronary artery disease
CHD  coronary heart disease
FH  familial hypercholesterolemia
HDL  high density lipoprotein
HMG-CoA  hepatic hydroxymethylglutaryl-coenzyme A
ISDN  isosorbide dinitrate
IVUS  intravascular ultrasound
LDL  low density lipoprotein
LDL-A  low density lipoprotein-apheresis
MI  myocardial infarction
MLD  minimal lumen diameter
NTG  nitroglycerin
PA  plaque area
PTCA  percutaneous transluminal coronary
angioplasty
QCA  quantitative coronary angiogram
TAC  time-averaged concentrations
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Coronary angiography. Coronary angiograms were ob-
tained at the outset and after one year of treatment under
the same conditions. During both procedures, the same
cineangiographic techniques were used, according to stan-
dard methods for quantitative analysis. After intracoronary
injection of an optimal amount nitroglycerin (NTG) (0.3 to
0.5 mg) or isosorbide dinitrate (ISDN) (5 mg) coronary
angiography was performed. Angiograms were obtained in
the 15° to 30° right anterior oblique and 40° to 60° left
anterior oblique projections. An evaluation committee con-
sisting of three experienced cardiologists blinded to lipid
levels and treatment allocation viewed baseline and
follow-up coronary arteriograms of each patient simulta-
neously on a double projector. Matching segments in both
coronary arteriograms were carefully selected by use of
identical projections.
After visual evaluation, quantitative analysis was per-
formed using the automated edge-detection method of
CARDIO 500 (Kontron, Munich, Germany). For calibra-
tion, the boundaries of a nontapering part of the catheter
were determined automatically over a length of approxi-
mately 2 cm. Following selection of the boundaries of a
segment, the arterial borders were defined by an automated
edge-detection algorithm, and the MLD was calculated
automatically for each available segment.
IVUS. The IVUS studies were performed at the outset and
after one year of follow-up, using a single-element 30 MHz,
2.9 or 3.2F intracoronary ultrasound catheter (Cardiovas-
cular Imaging Systems/Boston Scientific, Fremont, Califor-
nia, or Hewlett-Packard, Palo Alto, California, respective-
ly). After completion of the coronary angiography, optimal
doses of intracoronary NTG or ISDN were administered
for the prevention of catheter-induced coronary spasm. The
IVUS catheter was advanced into the distal portion of the
coronary artery, and it was then withdrawn proximally at a
constant speed (1 mm/s) with a motorized pullback device
(Cardiovascular Imaging Systems/Boston Scientific). The
IVUS images were continuously recorded on S-VHS vid-
eotape. An evaluation committee blinded to lipid levels and
treatment allocation selected the target coronary segments
by the presence of an easily definable and reproducible
branch point or calcified plaque to assist in the accurate and
serial assessment of the region of interest.
In details, the target plaque qualified for the present study
if it had not been influenced by any previous therapeutic
intervention, if the diameter stenosis was 50% on QCA,
and if the plaque was detected by IVUS. Four average
segments per patients were selected for IVUS evaluation.
Quantitative analysis of IVUS images in end-diastolic phase
was performed off-line using specialized computer software
(CARDIO 500, Kontron). Individual frames were digi-
tized, and the following measurements were obtained: 1)
cross-sectional vessel areas within the external elastic lam-
ina, 2) lumen cross-sectional areas, and 3) plaque area (PA),
which was calculated as external elastic area minus lumen
area. Because media thickness cannot be measured accu-
rately by the IVUS system, calculated PA including the
media cross-sectional area was used as a measurement of the
amount of atherosclerotic plaque. The IVUS images were
analyzed by two reviewers who were unaware of treatment
assignment. Measurements were averaged over five frames
from the study segments.
Statistical analysis. Analyses were performed using two-
way repeated-measures analysis of variance (ANOVA) for
the interaction of both treatments. All analyses were done
by the SAS system (SAS Institute Inc., Cary, North
Carolina). For categorical variables within the patient char-
acteristics, the chi-square test was used to compare the
differences in proportions or trends for both treatment
groups. In the LDL-A group, we calculated the TAC of
total cholesterol and LDL cholesterol because the rebound
curves were not linear. All values were expressed as means
SD, and a two-sided probability value of 0.05 was
considered statistically significant.
RESULTS
Baseline characteristics. Nineteen patients with FH (14
men and 5 women) were included and underwent a first
coronary angiography. Of these, one patient in the LDL-A
group was unable to complete a second angiogram at the
one-year follow-up because of severe respiratory failure;
consequently, this patient was not involved in the analysis.
Eleven heterozygous FH patients received biweekly LDL-A
combined with lipid-lowering drugs (LDL-A group) and
seven were given drug therapy alone (medication group).
The clinical characteristics at the outset (baseline) of the 18
patients who completed the study, according to treatment
allocation, are listed in Table 1. At baseline, the clinical,
hemodynamic and angiographic characteristics in the
LDL-A and medication groups were similar. No significant
differences existed between the groups in terms of age,
gender, risk factors, previous history, vessels with significant
stenosis and medications. There was a greater tendency of
Achilles’ tendon thickness in the LDL-A group than in the
medication group.
Lipid and lipoprotein profiles. Baseline levels of triglyc-
eride and HDL cholesterol in the LDL-A group were
similar to those in the medication group. However, total
cholesterol and LDL cholesterol in the LDL-A group were
higher than those in the medication group (275  27 mg/dl
vs. 251  57 mg/dl; 213  25 mg/dl vs. 174  39 mg/dl,
respectively). After one-year of treatment, serum levels of
total cholesterol and LDL cholesterol in the LDL-A group
showed 28.4% and 34.3% reduction in comparison to the
baseline, respectively (total cholesterol 275  27 mg/dl to
197  19 mg/dl; LDL-C 213  25 mg/dl to 140 
27 mg/dl), whereas, in the medication group, lipid levels
were not changed after one year of treatment. The p values
of the interaction of total cholesterol, triglycerides, LDL
cholesterol and HDL cholesterol with treatment analyzed
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using two-way repeated-measures ANOVA were 0.0001,
0.65, 0.0001 and 0.79, respectively (Table 2).
Analysis of coronary angiogram and IVUS. One hundred
and five lesions from the LDL-A group and 47 lesions from
the medication group were evaluated using paired measure-
ments of angiograms. The MLD was increased in the
LDL-A group during the one-year follow-up period (from
1.99  0.73 mm to 2.11  0.81 mm), whereas it was
decreased in the medication group (from 2.24  0.89 mm
to 2.16  0.84 mm). Thirty-four segments from the
LDL-A group and 14 lesions from the medication group
were evaluated using paired IVUS imaging. The PA was
decreased in the LDL-A group (from 8.45  4.22 mm2 to
7.76  4.34 mm2) over the one-year follow-up period,
whereas it was increased in the medication group (from
7.19  2.88 mm2 to 8.08  3.14 mm2). The changes of
lumen areas and vessel areas were limited in both the
LDL-A and medication groups over the one-year follow-up
period (Table 3). Net changes in parameters measured by
coronary angiogram and IVUS are shown in Figure 1. Net
changes in MLD during the one-year follow-up period were
significantly different between the LDL-A group and the
medication group (p 0.004) (Fig. 1A). Net changes in PA
were also significantly different between the two groups
(p  0.008) (Fig. 1B). However, no significant differences
existed in the net change in lumen area (Fig. 1C) and vessel
area (Fig. 1D) between the two groups. The p values of the
interaction of MLD, PA, lumen area and vessel area with
treatment analyzed using two-way repeated-measures
ANOVA were 0.008, 0.017, 0.52 and 0.26, respectively
(Table 3).
Representative examples of coronary angiograms and
IVUS images in a patient treated with combined LDL-A
and cholesterol-lowering drugs over the one-year follow-up
period are shown in Figure 2.
DISCUSSION
Results of the present study demonstrate that one-year
treatment with pravastatin (20 mg/day) or simvastatin
(10 mg/day) and other lipid-lowering drugs in combination
with biweekly LDL-A led to marked regression in coronary
plaques in comparison to medication alone in FH patients.
Effect of LDL-A on coronary plaque in FH patients.
Considering that the number of patients with three-vessel
stenosis was larger in the LDL-A group compared with the
medication group (based on the patients’ backgrounds at
registration) and that baseline LDL cholesterol level was
significantly higher and Achilles’ tendon thickness far more
progressed in the LDL-A group, it is possible that patients
with severe FH or progressed coronary artery disease
(CAD) tended to be assigned to the LDL-A group.
However, total cholesterol and LDL cholesterol in the
Table 1. Baseline Characteristics of Patients
LDL-A
Group
(n  11)
Medication
Group
(n  7)
Age (yrs) 50  13 54  15
Gender
Male 8 (73) 5 (71)
Female 3 (27) 2 (29)
Risk factor
Hypertension 4 (36) 4 (57)
Diabetes mellitus 2 (18) 0 (0)
Smoking 7 (64) 4 (57)
Past history
Angina pectoris 8 (73) 4 (57)
Old myocardial infarction 6 (55) 2 (29)
PTCA 5 (45) 5 (71)
CABG 2 (18) 1 (14)
Number of vessels with significant stenosis
1 1 (9) 2 (29)
2 3 (27) 2 (29)
3 7 (64) 3 (43)
Medication
Statin 11 (100) 7 (100)
Probucol 5 (45) 3 (43)
Cholestyramine 3 (27) 1 (14)
Fibrate 1 (9) 0 (0)
Nitrate 10 (91) 4 (57)
Other antiangina agents 4 (36) 0 (0)
Beta-blockers 3 (27) 2 (29)
Calcium antagonists 6 (55) 4 (57)
ACE inhibitors 1 (9) 2 (29)
Aspirin 7 (64) 4 (57)
Antidiabetics 3 (27) 0 (0)
Platelet aggregation inhibitors 4 (36) 2 (29)
Warfarin 2 (18) 1 (14)
Others 8 (73) 3 (43)
Achilles’ tendon thickness (mm)
Right 14.3  3.5 9.3  5.5
Left 14.5  4.3 10.0  6.0
Values are given as numbers (percentages) or mean  SD.
ACE  angiotensin-converting enzyme; CABG  coronary artery bypass graft
surgery; LDL-A  low density lipoprotein-apheresis; PTCA  percutaneous
transluminal coronary angioplasty.
Table 2. Change in Serum Lipid Levels
LDL-A Group (n  11) Medication Group (n  7)
p Value**Baseline Follow-Up Reduction* Baseline Follow-Up Reduction*
TC (mg/dl) 275  27 197  19 28.4 251  57 254  38 1.2 0.0001
TG (mg/dl) 143  74 139  93 2.8 163  70 147  41 9.8 0.65
HDL-C (mg/dl) 33  20 36  16 9.1 44  20 45  22 2.3 0.79
LDL-C (mg/dl) 213  25 140  27 34.3 174  39 181  53 4 0.0001
Data presented are mean value  SD. *(%). **Data obtained from two-way repeated-measures analysis of variance.
HDL-C  high density lipoprotein cholesterol; LDL-A  low density lipoprotein-apheresis; LDL-C  low density lipoprotein cholesterol; TC  total cholesterol; TG 
triglycerides.
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LDL-A group significantly decreased, by 28.4% and 34.3%,
respectively, in the one-year study period.
In contrast, in the medication group, both total choles-
terol and triglyceride levels increased slightly. Because
patients were already on HMG-CoA reductase inhibitor
when baseline lipid values were measured, changes in lipid
levels observed in the medication group were small and
quite different from those typically observed in many other
trials using HMG-CoA reductase inhibitors (10–14). Con-
sequently, the follow-up levels of total cholesterol and LDL
cholesterol in the LDL-A group were significantly lower in
comparison with the medication group.
Several clinical trials have demonstrated that lipid-
lowering therapy by HMG-CoA reductase inhibitors may
retard progression of coronary plaques despite the relatively
small changes in the severity of lesions demonstrated in
angiographic evaluations. In this study, no significant
change was detected in MLD, as determined by coronary
angiography, between the baseline and one-year follow-up
in the medication group, whereas a small but significant
increase in PA, as assessed by IVUS, was observed. These
results demonstrated that LDL cholesterol-lowering ther-
apy with drugs alone was insufficient, and the angiographi-
cal MLD of each segment did not change significantly;
moreover, the coronary PA measured directly by IVUS
increased gradually over one year of treatment.
In the LDL-A group, MLD was significantly increased
after one year of treatment, and it was comparable to MLDs
in previous LDL-A angiographic trials (15,16), but greater
than those in the lipid-lowering group using diet and drugs
in other angiographic studies (2,4,7). As evaluated by IVUS,
the PA was significantly decreased in the LDL-A group
after one year of follow-up. Takagi et al. (17) investigated
the effects of pravastatin lipid-lowering therapy using IVUS,
and they demonstrated that no significant change occurred
in the areas of lumen and whole blood vessels after a three-year
study period; however, the pravastatin group showed signifi-
cantly less progression than the control group with regard to
Table 3. Change in Parameters from Coronary Angiogram and IVUS
LDL-A Group Medication Group
p Value*Baseline Follow-Up Net Change Baseline Follow-Up Net Change
MLD (mm) 1.99  0.73 2.11  0.81 0.12 2.24  0.89 2.16  0.84 0.08 0.008
Plaque area (mm2) 8.45  4.22 7.76  4.34 0.69 7.19  2.88 8.08  3.14 0.88 0.017
Lumen area (mm2) 9.84  5.43 9.87  5.55 0.03 9.13  4.33 8.63  3.18 0.51 0.52
Vessel area (mm2) 18.29  8.84 17.63  9.05 0.66 16.4  5.63 19.0  4.36 0.3 0.26
Data presented are mean value  SD. *Data obtained from two-way repeated-measures analysis of variance.
IVUS  intravascular ultrasound; LDL-A  low density lipoprotein-apheresis; MLD  minimal lumen diameter.
Figure 1. Net change in coronary angiogram and intravascular ultrasound parameters. The open columns show the medication (med) group and the solid
columns the low density lipoprotein-apheresis (LDL-A) group. Net changes of minimal lumen diameter (MLD) (0.12  0.43 mm in the LDL-A vs.
0.08  0.45 mm in the medication group, p  0.004) during one-year follow-up showed significant differences in both the LDL-A group and the
medication group. The average net change of MLD was positive in the LDL-A group, whereas it was negative in the medication group (A). Net changes
of plaque area (0.69  2.08 mm2 in the LDL-A vs. 0.88  1.75 mm2 in the medication group, p  0.008) were also significantly different between the
LDL-A group and the medication group. The average net change of plaque area was negative in LDL-A subjects, while it was positive in medication
subjects (B). No significant differences were seen in net change of lumen area (C, p  0.13) and vessel area (D, p  0.26) between the two groups.
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PA. To our knowledge, the present study is the first one to
directly evaluate the combined effect of lipid-lowering drug
therapy and LDL-A on coronary plaque using IVUS in severe
hypercholesterolemic patients with CAD.
Possible role of LDL-A. Regression and/or retardation of
coronary atherosclerosis (15,16,18) and reduction of cardiac
event (19) have proved to be the major treatment effects of
LDL-A. Several possible mechanisms have been suggested
for the reduction in cardiac events—for example, improve-
ment in vascular endothelial functions (20), stabilization of
plaques (21), prolongation in oxidizability of low density
lipoprotein (22,23), reduction or suppression of the expres-
sion of adhesion molecules (24,25) and suppression of
platelet activation (26). The present study is the first to
focus on quantification of the changes occurring in athero-
sclerotic plaque after LDL-A therapy, and it has demon-
strated marked regression of coronary plaques by measure-
ment with IVUS. The finding that aggressive lipid-lowering
treatment in combination with LDL-A and lipid-lowering
drugs leads to regression of coronary plaques indicated a
possible role for the therapy in the restructuring and
stabilization of coronary plaque, and in the prevention of the
development of cardiac events.
Clinical implications. Concern regarding acute coronary
syndrome has recently been growing, and it is now recog-
nized that regression and stabilization of coronary plaque is
critical for prevention of its development. It is expected that
aggressive lipid-lowering therapy using LDL-A could be
beneficial not only for patients with drug refractory hyper-
cholesterolemia, but also for patients with CHD at high risk
of acute coronary syndrome as a strategy of treatment to
modify the process of coronary remodeling and stabilization
of atherosclerotic plaque. Recent study (ASAP) reported
that aggressive LDL cholesterol reduction by atorvastatin
was accompanied by regression of carotid intima media
thickness in patients with FH (27). It was easy to recruit the
study patients, and there was no ethical problem on the
randomized study in the ASAP trials because it included
Figure 2. Representative examples of coronary angiograms and intravascular ultrasound (IVUS) images are shown in a patient treated with combined low
density lipoprotein-apheresis and cholesterol-lowering drugs for one year. In coronary angiograms (A and B in baseline and follow-up, respectively), the
minimal lumen diameter (MLD) at the left anterior descending coronary artery (LAD) increased from 1.5 to 2.2 mm. Panels C and D show the same
portion using IVUS imaging. The plaque area was decreased from 7.8 to 7.0 mm2, which was associated with an increase in the lumen area from 3.3 to
5.3 mm2. The vessel area also changed, from 11.1 to 12.3 mm2. The image in D2 is the second diagonal branch as the reference vessel.
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patients without CHD, and severity of coronary atheroscle-
rosis was relatively mild. In the present study, randomiza-
tion was ethically impossible because the patients included
in this study had history of CHD and severe coronary
atherosclerosis, and lipid levels in all patients were not well
controlled by using full medications with lipid-lowering
drugs. The use of atorvastatin was not approved by the
Japanese Ministry of Health and Welfare during the course
of the present study. Atorvastatin was marketed in 2000,
and the maximal clinical dose of atorvastatin was 40 mg per
day in Japan. We hope that a comparative study with
atorvastatin will be conducted in the near future.
Study limitations. In this study, the following limitations
should be noted. First, the number of study patients was
small owing to the strict inclusion criteria. In particular, the
number of subjects in the medication group was limited
because of the nonrandomized nature of the present study.
Second, although baseline patient characteristics between
the two groups were similar, the study was prospective and
controlled but not randomized. Third, only a small portion
of the epicardial coronary vasculature was studied by IVUS.
Finally, because the present study aimed at evaluation of
changes in coronary plaques over a relatively short period
(i.e., one-year) and involved a small number of patients,
analysis of the incidence of events was not possible.
Conclusions. Aggressive LDL cholesterol-lowering ther-
apy in combination with LDL-A and administration of
basic lipid-lowering drugs over a period of a year is
associated with a statistically significant regression of coro-
nary artery lesions in FH patients with advanced CAD
compared with FH patients treated with medication alone.
Therefore, LDL-A should be considered as an effective
treatment for FH patients with CAD and high LDL
cholesterol levels who are receiving maximally tolerated
combination of lipid-lowering drug therapy.
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